PD-1/PD-L1
Os inibidores de PD-1/PD-L1 são inibidores de checkpoints imunológicos que bloqueiam a interação entre a proteína de morte celular programada 1 (PD-1) nas células T e seu ligante PD-L1 nas células cancerígenas. Essa interação normalmente suprime a resposta imunológica e permite que as células cancerígenas evitem a detecção imunológica. Ao inibir PD-1/PD-L1, esses inibidores aumentam a capacidade do sistema imunológico de reconhecer e destruir células cancerígenas, induzindo apoptose e regressão tumoral. Os inibidores de PD-1/PD-L1 são fundamentais na pesquisa em imunoterapia e no tratamento do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PD-1/PD-L1 de alta qualidade para apoiar sua pesquisa em imunooncologia, apoptose e terapia do câncer.
Foram encontrados 150 produtos para "PD-1/PD-L1".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Cor e Forma:Odour SolidPD-L1 inhibitory peptide
CAS:PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Fórmula:C96H135N21O23SCor e Forma:SolidPeso molecular:1983.29Human PD-L1 inhibitor IV
CAS:PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Fórmula:C80H113N25O27Cor e Forma:SolidPeso molecular:1856.932Human PD-L1 inhibitor III
CAS:Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Fórmula:C97H155N29O29SCor e Forma:SolidPeso molecular:2223.54RTX-002
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. This compound is applicable in the research of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.Cor e Forma:Odour LiquidPD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.Cor e Forma:Odour SolidPD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Fórmula:C23H20ClFN2O3Cor e Forma:SolidPeso molecular:426.11465PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.Cor e Forma:Odour SolidOPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.Fórmula:C64H92N20O19SPeso molecular:1476.65683Garivulimab
CAS:Garivulimab (BGB-A333) is a humanized mAb targeting PD-L1 that enhances T-cell anti-tumor activity by blocking the PD-1/PD-L1 pathway.Pureza:95%Cor e Forma:Transparent LiquidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Fórmula:C22H24N2O2Pureza:99.92%Cor e Forma:SolidPeso molecular:348.44Ref: TM-T9651
10mgA consultar25mgA consultar50mgA consultar100mgA consultar500mgA consultar1mg57,00€2mg85,00€5mg127,00€1mL*10mM (DMSO)140,00€Camrelizumab
CAS:Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of upPureza:98.5% (SDS-PAGE); 98.2% (SEC-HPLC) - 98.6%Cor e Forma:LiquidPeso molecular:143.69 kDaPD-1/PD-L1-IN-49
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.Fórmula:C27H32N4O5Cor e Forma:SolidPeso molecular:492.567Pacmilimab
CAS:Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Pureza:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:153.3 kDaAUNP-12
CAS:AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Fórmula:C142H226N40O48Pureza:98%Cor e Forma:SolidPeso molecular:3261.55Prolgolimab
CAS:Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.Pureza:>95%Cor e Forma:Transparent LiquidPeso molecular:146.28 kDaIparomlimab
CAS:Iparomlimab serves as a functional therapeutic tool specifically designed to enable the precise detection and neutralization of the PD-1 protein which plays a pivotal role in the induction of peripheral tolerance and tumor immune evasion during strictly monitored laboratory observation periods and molecular investigations to evaluate the pharmacological potential of targeted checkpoint inhibition in specialized preclinical research environments to facilitate the study of cancer immunotherapies.Pureza:95%Cor e Forma:Transparent LiquidPD-1/PD-L1-IN-40
PD-1/PD-L1-IN-40 (Compound EP16) is a PD-1/PD-L1 inhibitor. It effectively suppresses the production of exosomal PD-L1 with an IC50 of 0.108 μM. PD-1/PD-L1-IN-40 serves as a lead compound for the elimination of exosomal PD-L1 and is applicable in cancer research.Fórmula:C20H22N4O2Cor e Forma:SolidPeso molecular:350.17428Human membrane-bound PD-L1 polypeptide
CAS:Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].Fórmula:C85H140N26O36SPureza:98%Cor e Forma:SolidPeso molecular:2134.24Manelimab
CAS:Manelimab is an IL-10Ra-activating immunocytokine that exerts potent anti-inflammatory and immunomodulatory effects by mimicking the IL-10 signaling pathway.Cor e Forma:Liquid
